SCHEMBL15569877

SCHEMBL15569877

NC(=O)C(Nc1cncc(-c2cncc(Cl)c2)c1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.47
MKNK1 Q9BUB5 2/20 0.47
MKNK2 Q9HBH9 2/20 0.47
FDPS P14324 1/20 0.46
CYP3A4 P08684 2/20 0.44
CYP2C9 P11712 2/20 0.44
MAPK1 P28482 2/20 0.44
PDGFRA P16234 1/20 0.44
MAPKAPK2 P49137 1/20 0.44
RPS6KA1 Q15418 1/20 0.44
AURKB Q96GD4 1/20 0.44
CSNK1G1 Q9HCP0 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
KCNH2 Q12809 1/20 0.43
PTGES O14684 2/20 0.42
CCNC P24863 1/20 0.41
CDK8 P49336 1/20 0.41
XDH P47989 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15569878 0.86 XDH (0.54) CNR1FDPSCYP3A4CYP2C9MAPK1
SCHEMBL15570215 0.85 XDH (0.47) CNR1FDPSCYP3A4CYP2C9MAPK1
SCHEMBL15569764 0.85 XDH (0.47) CNR1FDPSCYP3A4CYP2C9MAPK1
SCHEMBL31624680 0.85 XDH (0.47) CNR1FDPSCYP3A4CYP2C9MAPK1
SCHEMBL15569128 0.85 CNR1 (0.46) CNR1FDPSCYP3A4CYP2C9MAPK1
SCHEMBL15569129 0.85 CNR1 (0.46) CNR1FDPSCYP3A4CYP2C9MAPK1
SCHEMBL15569765 0.85 XDH (0.47) CNR1FDPSCYP3A4CYP2C9MAPK1
SCHEMBL15799500 0.82 CDK7 (0.51) CCNCCDK8
SCHEMBL15799406 0.82 CDK7 (0.51) CCNCCDK8
SCHEMBL15799405 0.82 CDK7 (0.51) CCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458106-B2 Phenyl-pyridine/pyrazine amides for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2016-10-04 US claimed
EP-2888232-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2015-07-01 EP claimed
US-20150158815-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2015-06-11 US claimed
WO-2014029726-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2014-02-27 WO claimed
US-9458106-B2 Phenyl-pyridine/pyrazine amides for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2016-10-04 US disclosed
US-9458106-B2 Phenyl-pyridine/pyrazine amides for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2016-10-04 US disclosed
EP-2888232-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2015-07-01 EP disclosed
US-20150158815-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2015-06-11 US disclosed
US-20150158815-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2015-06-11 US disclosed
WO-2014029726-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2014-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158815-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER TP53, RB1, HCCS CNR1 338/4885MKNK1 1281/4885MKNK2 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.